(601089)"BEIJING FOYOU PHARMA CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 601089 · · 12 pages · Chinese
Summary by 6ix AI
The report indicates a decrease in net profit attributable to shareholders compared to the same period last year, primarily due to price declines and increased research and development costs. The financial statements included in the report are unaudited, and the company assures the accuracy and completeness of the information provided.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Beijing Foyou Pharma Co., Ltd. on 6ix
Earlier from Beijing Foyou Pharma
- (601089)"BEIJING FOYOU PHARMA CO., LTD."Announcement on Obtaining Drug Registration Certificate for Rotigotine Patches
- Announcement on Pledge of Shares Held by Persons Acting in Concert with the Controlling Shareholder
- Announcement on Obtaining Drug Registration Certificate for Bromocriptine Mesylate Tablets
- Announcement on the Completion of Raised-Fund Investment Projects
- Announcement on Convening the 2026 Semi-annual Performance Briefing
Later from Beijing Foyou Pharma
All Beijing Foyou Pharma news releasesFollow Beijing Foyou Pharma into a list and get an email when it puts out news.
Follow Beijing Foyou Pharma